{
  "meta": {
    "title": "Organ_Transplantation_Graft_Versus_Host_Disease",
    "url": "https://brainandscalpel.vercel.app/organ-transplantation-graft-versus-host-disease-07afef92.html",
    "scrapedAt": "2025-11-29T18:32:10.829Z"
  },
  "questions": [
    {
      "id": 14177,
      "choices": [
        {
          "id": 56669,
          "text": "<p><span style=\"font-size:12pt;\">Skin</span></p>"
        },
        {
          "id": 56670,
          "text": "<p><span style=\"font-size:12.0pt;\">GIT</span></p>"
        },
        {
          "id": 56671,
          "text": "<p><span style=\"font-size:12pt;\">Liver</span></p>"
        },
        {
          "id": 56672,
          "text": "<p><span style=\"font-size:12pt;\">Lung</span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">A 55-year-old female patient, six weeks post-hematopoietic stem cell transplantation, presents with a widespread rash, severe diarrhea, and jaundice. She underwent transplantation for acute myelogenous leukemia and received cells from a matched unrelated donor. Which organ is least likely to be affected by graft-versus-host disease (GVHD) in this patient?</span></p>",
      "unique_key": "Q4094692",
      "question_audio": null,
      "question_video": null,
      "map_id": 31855,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. D) Lung</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>GVHD </strong>affects <strong>skin (earliest organ), intestine and liver&nbsp;</strong> Lungs are <strong>not </strong>affected in GVHD.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Lung:</strong> </span><span style=\"font-size:12.0pt;\">It is LEAST likely to be affected.&nbsp;L</span><span style=\"font-size:12pt;\">ung can be involved in <strong>chronic GVHD</strong>, manifesting as <strong>bronchiolitis obliterans, </strong>it is not commonly affected in acute GVHD, which typically involves the skin, GIT, and liver.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A: Skin:</strong> The skin is often the<strong> earliest and most commonly affected organ in GVHD</strong>, presenting with <strong>rash </strong>and potential progression to <strong>desquamation.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B: GIT (Gastrointestinal Tract):</strong> The GIT is a major target in<strong> GVHD</strong>, often manifesting as <strong>diarrhea, </strong>which can range from <strong>mild to severe, </strong>and may be associated with <strong>abdominal pain and bleeding.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C: Liver:</strong> Hepatic involvement in GVHD typically presents with jaundice and elevated liver enzymes, which can progress to severe liver dysfunction.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">In<strong> GVHD, the skin, GIT, and liver are commonly involved</strong>, while the<strong> lungs are less frequently </strong>affected, particularly in the <strong>acute phase of the disease</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>(Ref: Robbins 10<sup>th</sup>/ 236)</strong></span></p>",
      "correct_choice_id": 56672,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14165,
      "choices": [
        {
          "id": 56621,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preformed antibodies </span></span></span></p>"
        },
        {
          "id": 56622,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cytotoxic T-lymphocyte mediated injury </span></span></span></p>"
        },
        {
          "id": 56623,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Circulating macrophage mediated injury </span></span></span></p>"
        },
        {
          "id": 56624,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endothelitis caused by donor antibodies </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperacute rejection is due to?</span></span></span></p>",
      "unique_key": "Q3826703",
      "question_audio": null,
      "question_video": null,
      "map_id": 31858,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Preformed antibodies </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&lsquo;<strong>Hyperacute rejection </strong>occurs when <strong>preformed antidonor antibodies </strong>are present in the circulation of the recipient&rsquo;</span></em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Preformed antibodies:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hyperacute rejection is mediated by preformed antibodies in the recipient that immediately react with the graft, leading to rapid thrombosis and ischemia of the transplanted organ.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Cytotoxic T-lymphocyte mediated injury:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While cytotoxic T-lymphocytes play a crucial role in cellular rejection, they are not typically involved in the immediate rejection seen in hyperacute reactions, which occur due to the presence of pre-existing antibodies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Circulating macrophage mediated injury:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Macrophages are involved in antibody-mediated responses and can contribute to cellular rejection; however, they are not the primary mediators of hyperacute rejection.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: Endothelitis caused by donor antibodies:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Endothelitis is associated with acute and chronic rejection due to the recipient&#39;s immune response against the donor endothelium, not the other way around. Donor antibodies do not cause hyperacute rejection.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The presence of preformed antibodies against donor antigens in the recipient&#39;s blood is the primary cause of hyperacute rejection. This type of rejection can occur due to prior sensitization to HLA antigens through pregnancy, blood transfusions, or previous transplants</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><em><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ 233-234) </span></span></em></strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><em><span style=\"font-size:12.0pt\"> </span></em></strong></span></span></p>",
      "correct_choice_id": 56621,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14160,
      "choices": [
        {
          "id": 56601,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute rejection</span></span></span></p>"
        },
        {
          "id": 56602,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperacute rejection</span></span></span></p>"
        },
        {
          "id": 56603,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic rejection</span></span></span></p>"
        },
        {
          "id": 56604,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graft versus host disease</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Runt disease is associated with:</span></span></span></p>",
      "unique_key": "Q2593698",
      "question_audio": null,
      "question_video": null,
      "map_id": 31856,
      "difficulty_level": "beginner",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span dir=\"ltr\" lang=\"DE\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Graft versus host disease</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graft versus Host Disease (GVHD):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> GVHD occurs in the context of bone marrow or stem cell transplants when immunocompetent donor T cells recognize the recipient&#39;s tissues as foreign and initiate an immune response against them. It can present acutely or chronically and can affect various organs, including the skin, liver, and gastrointestinal tract.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Acute Rejection:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a cell-mediated immune response that occurs days to months after transplantation. It involves direct cytotoxicity and inflammation, primarily affecting solid organ transplants, not typically associated with bone marrow transplants.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Hyperacute Rejection:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This type of rejection occurs within minutes to hours after transplantation due to pre-existing antibodies in the recipient against graft antigens, leading to rapid thrombosis and necrosis of the graft. It is usually associated with organ transplants.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Chronic Rejection:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Chronic rejection is a long-term process where the graft is slowly lost over months to years due to a complex interplay of cellular and humoral immune responses. It often manifests as a gradual loss of function of the transplanted organ.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GVHD, exemplified by &quot;runt disease&quot; in the question, is a condition wherein immunocompetent cells from a donor mount an immune response against the host&#39;s tissues. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup>/ p236)</span></strong></span></span></p>",
      "correct_choice_id": 56604,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14161,
      "choices": [
        {
          "id": 56605,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C3d </span></span></span></p>"
        },
        {
          "id": 56606,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C5a</span></span></span></p>"
        },
        {
          "id": 56607,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C3b </span></span></span></p>"
        },
        {
          "id": 56608,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C4d</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient who has undergone kidney transplantation and is now presenting with signs of renal dysfunction, which complement activation product is a known histological marker for the diagnosis of antibody-mediated rejection in transplant biopsies?</span></span></span></p>",
      "unique_key": "Q4208445",
      "question_audio": null,
      "question_video": null,
      "map_id": 31857,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) C4d </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C4d:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C4d is a split product of the <strong>complement protein C4 </strong>and is considered a<strong> specific </strong>marker for the <strong>classic pathway of complement</strong> activation in the context of <strong>antibody-mediated rejection.</strong> Its presence in <strong>peritubular capillaries</strong> is associated with the <strong>rejection</strong> process.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: C3d:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C3d is a breakdown product of the complement<strong> component C3 </strong>and can indicate <strong>complement activation</strong>, but it is <strong>not the most specific marker for antibody-mediated rejection.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: C5a:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C5a is an <strong>anaphylatoxin </strong>produced during complement activation that has potent inflammatory effects and can <strong>recruit neutrophils and macrophages</strong>. While it plays a role in<strong> inflammation</strong>, it is<strong> not </strong>typically used as a histological marker for <strong>antibody-mediated rejection.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: C3b:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> C3b is another breakdown product of C3 and<strong> acts as an opsonin </strong>that promotes <strong>phagocytosis and further complement activation. </strong>It is not specifically used as a marker for antibody-mediated rejection in transplant patients.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>C4d</strong> is the specific histological marker used to identify <strong>antibody-mediated rejection in organ transplants</strong>. Its detection is <strong>significant for the diagnosis and management of this type of rejection</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Ref: Robbins 10<sup>th</sup> 238)</span></span></strong></p>",
      "correct_choice_id": 56608,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 14172,
      "choices": [
        {
          "id": 56649,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">T-cell removal </span></span></span></p>"
        },
        {
          "id": 56650,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prior immune suppression </span></span></span></p>"
        },
        {
          "id": 56651,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post procedure immune suppression </span></span></span></p>"
        },
        {
          "id": 56652,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the above </span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which combination of strategies is employed to minimize the risk of graft-versus-host disease (GVHD) following bone marrow transplantation? </span></span></span></p>",
      "unique_key": "Q2945442",
      "question_audio": null,
      "question_video": null,
      "map_id": 31859,
      "difficulty_level": "intermediate",
      "subjects_id": [
        5
      ],
      "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) All of the above </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the Above:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> All the listed methods are <strong>integrated approaches </strong>to prevent <strong>GVHD. </strong>This includes matching <strong>donor and recipient HLA types </strong>as closely as possible, the <strong>use of immunosuppressive drugs</strong>, <strong>T-cell depletion of the graft, </strong>and <strong>post-transplant immunosuppression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: T-cell Removal:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> T-cell depletion from the<strong> donor graft </strong>is a method used to reduce the<strong> incidence and severity of GVHD </strong>by removing the cells most responsible for the <strong>alloreactive response</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Prior Immune Suppression:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Immunosuppressive therapy prior to<strong> transplantation </strong>can reduce the<strong> recipient&#39;s immune response </strong>to the donor graft and is used to condition the recipient.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Post Procedure Immune Suppression:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Following the<strong> transplantation, immunosuppressive </strong>drugs such as <strong>methotrexate and cyclophosphamide </strong>are used to further<strong> prevent GVHD.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> prevention of GVHD in bone marrow transplantation </strong>involves a<strong> multimodal approach</strong>, including <strong>optimal donor matching, pre-transplant </strong>conditioning with <strong>immunosuppressive drugs, T-cell depletion of the donor marrow, and post-transplant immunosuppression</strong>. </span></span></p>",
      "correct_choice_id": 56652,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}